Akari Therapeutics, Plc (AKTX)

Compare

1.1000

-0.0500

(-4.35%)

At close: 4:00:00 PM EDT

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B Held several executive leadership roles at Amgen, Pfizer, and Johnson & Johnson across multiple brands including Kyprolis®, Vectibix®, Neulasta®, XGEVA®, Repatha®, and ELIQUIS® Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company’s Board of Di

GlobeNewswire 13 days ago

AKTX
-4.35%
Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

BOSTON and LONDON, March 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $7.6 million in gross proceeds. With these funds the Company will focus on investing in its novel spliceosome inhibitor payl

GlobeNewswire 30 days ago

AKTX
-4.35%
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced it participated in the Virtual Investor “Top 5 for ‘25” On-Demand Conference. As part of the event, Dr. Samir Patel, President and Chief Executive Officer of Akari Therapeutics, presented the top five reasons of w

GlobeNewswire last month

AKTX
-4.35%
Akari Therapeutics Joins Webull Corporate Connect Service Platform

Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here BOSTON and LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform. Akari’s portal on the Webull CCS ai

GlobeNewswire last month

AKTX
-4.35%
Akari Therapeutics Announces Key Leadership Appointments

Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Samir R. Patel, M.D., as Chief Executive Officer, effective December 16, 2024. Dr. Patel has served as interim Chief Executive Officer since May 2024. Additionally, the Company announced it has appointed Abizer Gaslightwala to its Board of Directors, effective D

GlobeNewswire 3 months ago

AKTX
-4.35%
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck is a seasoned executive with over 20 years of experience in the biotechnology industry, finance, capital markets and M&A transactions, as well as clinical and commercial product development and regulatory filings in the U.S. and Europe. “We are pleased with the continued evolution

GlobeNewswire 3 months ago

AKTX
-4.35%
Akari Therapeutics Regains Full Nasdaq Compliance

- Shareholders Equity Deficiency has been Cured - - Akari will Continue to be Listed and Traded on The Nasdaq Stock Market - BOSTON and LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) announces receipt of written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that its deficiency under Listing Rule 5550(b) has been cured. The Company is now in full compliance with all Nasdaq continued listing requirements. Based o

GlobeNewswire 4 months ago

AKTX
-4.35%
This Akari Therapeutics Insider Increased Their Holding By 69% Last Year

Viewing insider transactions for Akari Therapeutics, Plc's ( NASDAQ:AKTX ) over the last year, we see that insiders...

Simply Wall St. 4 months ago

AKTX
-4.35%
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

- Secures $3.2m in PIPE Financing -- $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - BOSTON and LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) announces the completion of the merger (the Merger) of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. (Peak Bio), creating an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies. The combined entity will continue the two companies’

GlobeNewswire 4 months ago

AKTX
-4.35%
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company’s offices in London, shareholders approved the Company’

GlobeNewswire 4 months ago

AKTX
-4.35%
PKBO

PKBOW
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the Gen

GlobeNewswire 5 months ago

PKBO

PKBOW

AKTX
-4.35%
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics

BOSTON and LONDON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the appointment of Rob Bazemore, experienced life sciences leader, to the Akari Board of Directors effective September 17, 2024. “I am very honored to have the opportunity to work with this distinguished board of directors to advance the portfolio opportunities,” said Mr. Bazemore. “Focu

GlobeNewswire 6 months ago

AKTX
-4.35%
PKBO

PKBOW
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy Existing Investors Support the Company with Issuance of $1 Million in Unsecured Convertible Notes Secured $7.6 Million in Upsized Financing Round Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographi

GlobeNewswire 7 months ago

AKTX
-4.35%
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophyBOSTON and LONDON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics announced today that the company has received positive and constructive Pre-IND (PIND) feedback from the FDA on July 29, 2024, which provides additional clarity on Akari’s final Investigational New Drug Application (IND)- enabling preclinical plans, drug manufacturing and

GlobeNewswire 7 months ago

AKTX
-4.35%
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders

Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr

GlobeNewswire 9 months ago

AKTX
-4.35%
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round

BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $7.6 million in gross proceeds from both new and existing investors. "We are pleased to announce this financing for Akari Therapeutics," said Samir R. Pate

GlobeNewswire 9 months ago

AKTX
-4.35%
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy Implementation of Restructuring Plan to Reduce Operating Costs Existing Investors Support the Company with Issuance of $1 million in Unsecured Convertible Notes BOSTON and LONDON, May 16, 2024 (GLOBE NEWSWIRE) -- Akari The

GlobeNewswire 10 months ago

AKTX
-4.35%
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO. Rachelle Jacques will step down as Akari’s Chief Executive Officer effective today. Melissa Bradford-Klug will step down as Akari’s Chief Operating Officer effective today

GlobeNewswire 10 months ago

AKTX
-4.35%
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following com

GlobeNewswire 10 months ago

AKTX
-4.35%
PKBO

PKBOW
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. Akari Chief S

GlobeNewswire 11 months ago

AKTX
-4.35%

Performance Overview

Return	AKTX	MSCI WORLD (^990100-USD-STRD)
YTD	+10.00%	-1.06%
1-Year	-27.15%	+7.79%
3-Year	-95.34%	+20.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Akari Therapeutics, Plc (AKTX)

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Akari Therapeutics Announces Key Leadership Appointments

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Akari Therapeutics Regains Full Nasdaq Compliance

This Akari Therapeutics Insider Increased Their Holding By 69% Last Year

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders

Akari Therapeutics Secures $7.6 Million in Upsized Financing Round

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Performance Overview